CDK9/HDAC1/HDAC3-IN-1

CDK9/HDAC1/HDAC3-IN-1 is dual-functional inhibitor of CDK9 and HDAC. CDK9/HDAC1/HDAC3-IN-1 inhibits the protein activity of CDK9/HDAC/HDAC3 with IC50 s of 0.17 μM, 1.73 μM and 1.11 μM for CDK9, HDAC1, and HDAC3, respectively. CDK9/HDAC1/HDAC3-IN-1 inhibits cancer cells by inducing cell apoptosis and cell cycle arrest in the G2/M phase, as well as tumor growth in a murine TNBC MDA-MB-231 xenograft model. CDK9/HDAC1/HDAC3-IN-1 has a broad-spectrum anti-cancer activity, such as breast cancer, cervical cancer, and liver cancer[1].

Product Specifications

CAS Number

[2197029-81-3]

UNSPSC

12352005

Target

Apoptosis; CDK; HDAC

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Epigenetics

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Smiles

CNC1=NC(C)=C(S1)C2=NC(NC3=CC=C4C(C=C(C(NC5=CC=CC=C5N)=O)N4)=C3)=NC=C2

Molecular Formula

C24H22N8OS

Molecular Weight

470.55

References & Citations

[1]Chen X, et al. Design, synthesis, and biological evaluation of N- (2-amino-phenyl) -5- (4-aryl-pyrimidin-2-yl) amino) -1H-indole-2-carboxamide derivatives as novel inhibitors of CDK9 and class I HDACs for cancer treatment[J]. Bioorganic Chemistry, 2025: 108577.